The global diabetes market is experiencing a surge driven by the increasing prevalence of this chronic disease. At the forefront of this evolution are leading developers of GLP-1 receptor agonists, a class of drugs that have revolutionized diabetes treatment. These innovative medications emulate the actions of naturally occurring glucagon-like pept